OPKO Health, Inc. Acquisitions, Net of Cash Acquired
OPKO Health, Inc. (OPK) reported Acquisitions, Net of Cash Acquired of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2025-03-03
- OPKO Health, Inc. payments to acquire businesses, net of cash acquired for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- OPKO Health, Inc. payments to acquire businesses, net of cash acquired for the quarter ending 2023-09-30 was $0.00.
- OPKO Health, Inc. payments to acquire businesses, net of cash acquired for the quarter ending 2022-12-31 was $1.99M.
- OPKO Health, Inc. payments to acquire businesses, net of cash acquired for the quarter ending 2022-09-30 was -$2.30M, a 157.47% decline year-over-year.
- OPKO Health, Inc. payments to acquire businesses, net of cash acquired for fiscal 2024 was $0.00.
- OPKO Health, Inc. payments to acquire businesses, net of cash acquired for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- OPKO Health, Inc. payments to acquire businesses, net of cash acquired for fiscal 2022 was $1.76M, a 56.05% decline from fiscal 2021.
- OPKO Health, Inc. payments to acquire businesses, net of cash acquired for fiscal 2021 was $4.00M.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-03 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $0.00 derived: sum of 2 quarters · filed 2025-03-03 | $0.00 10-K · filed 2025-03-03 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $0.00 10-Q · filed 2023-11-06 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-03 | |||
| 2022-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$313.00K derived: sum of 2 quarters · filed 2025-03-03 | $1.76M 10-K · filed 2025-03-03 | |
| 2022-09-30 | -$2.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$228.00K 10-Q · filed 2023-11-06 | ||
| 2022-06-30 | $2.07M 10-Q · filed 2023-08-03 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $4.00M derived: sum of 2 quarters · filed 2024-03-01 | $4.00M 10-K · filed 2024-03-01 | |
| 2021-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $4.00M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 10-K · filed 2023-02-27 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-10-28 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 | |||
| 2018-12-31 | $0.00 10-K · filed 2019-03-01 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $0.00 10-K · filed 2019-03-01 | ||
| 2017-09-30 | $0.00 10-Q · filed 2017-11-08 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$15.88M derived: sum of 2 quarters · filed 2019-03-01 | -$15.88M 10-K · filed 2019-03-01 | |
| 2016-09-30 | -$15.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$15.88M 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | $0.00 10-Q · filed 2016-08-08 | |||
| 2015-12-31 | $138.00K derived: 8-K 12 month − 10-Q 9 month · filed 2019-01-29 | -$15.67M derived: sum of 2 quarters · filed 2019-01-29 | $79.00M derived: sum of 3 quarters · filed 2019-01-29 | $79.00M 8-K · filed 2019-01-29 |
| 2015-09-30 | -$15.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $78.86M derived: sum of 2 quarters · filed 2016-11-07 | $78.86M 10-Q · filed 2016-11-07 | $78.86M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $94.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $94.67M 10-Q · filed 2016-08-08 | $94.67M derived: sum of 3 quarters · filed 2017-03-01 | $94.66M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $0.00 10-Q · filed 2015-05-11 | $0.00 derived: sum of 2 quarters · filed 2017-03-01 | -$12.00K derived: sum of 3 quarters · filed 2017-03-01 | $1.48M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$12.00K derived: sum of 2 quarters · filed 2017-03-01 | $1.48M derived: sum of 3 quarters · filed 2017-03-01 | $1.68M 10-K · filed 2017-03-01 |
| 2014-09-30 | -$12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $1.48M derived: sum of 2 quarters · filed 2015-11-09 | $1.68M 10-Q · filed 2015-11-09 | $1.68M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $1.70M 10-Q · filed 2015-08-05 | $1.70M derived: sum of 3 quarters · filed 2016-02-29 | -$18.75M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $200.00K 10-Q · filed 2015-05-11 | $200.00K derived: sum of 2 quarters · filed 2016-02-29 | -$20.25M derived: sum of 3 quarters · filed 2016-02-29 | -$20.25M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$20.45M derived: sum of 2 quarters · filed 2016-02-29 | -$20.45M derived: sum of 3 quarters · filed 2016-02-29 | -$20.53M 10-K · filed 2016-02-29 |
| 2013-09-30 | -$20.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$20.45M derived: sum of 2 quarters · filed 2014-11-07 | -$20.53M 10-Q · filed 2014-11-07 | -$11.95M derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$78.00K 10-Q · filed 2014-08-11 | $8.50M derived: sum of 3 quarters · filed 2015-02-27 | $16.84M derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-03-31 | -$78.00K 10-Q · filed 2014-05-09 | $8.50M derived: sum of 2 quarters · filed 2015-02-27 | $16.84M derived: sum of 3 quarters · filed 2015-02-27 | |
| 2012-12-31 | $8.58M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $16.92M derived: sum of 2 quarters · filed 2015-02-27 | $19.09M 10-K · filed 2015-02-27 | |
| 2012-09-30 | $8.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $10.51M 10-Q · filed 2013-11-12 | ||
| 2012-06-30 | $2.17M 10-Q · filed 2013-08-09 | |||
| 2011-12-31 | $17.65M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $17.65M derived: sum of 2 quarters · filed 2014-03-03 | $17.65M derived: sum of 3 quarters · filed 2014-03-03 | $28.19M 10-K · filed 2014-03-03 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $0.00 derived: sum of 2 quarters · filed 2012-11-09 | $10.54M 10-Q · filed 2012-11-09 | $10.54M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $10.54M 10-Q · filed 2012-08-09 | $10.54M derived: sum of 3 quarters · filed 2013-03-18 | $10.41M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-03-31 | $10.54M 10-Q · filed 2012-05-10 | $10.54M derived: sum of 2 quarters · filed 2013-03-18 | $10.41M derived: sum of 3 quarters · filed 2013-03-18 | |
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | -$124.00K derived: sum of 2 quarters · filed 2013-03-18 | $1.32M 10-K · filed 2013-03-18 | |
| 2010-09-30 | -$124.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | $1.32M 10-Q · filed 2011-11-09 | ||
| 2010-06-30 | $1.45M 10-Q · filed 2011-08-08 | |||
| 2009-12-31 | $15.63M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |